Intravenous Cardioversion of Atrial Fibrillation (AF) With AZD1305

Status:
Completed

Trial end date:
2009-12-01

Target enrollment:

Participant gender:

This study is being carried out to see which dose of AZD1305 is safe and effective in cardioverting atrial fibrillation into normal heart rhythm.

Phase 2

AstraZeneca